Department of Cardiology, Medical University of Bialystok, Białystok, Poland.
1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland.
Kardiol Pol. 2021;79(12):1399-1410. doi: 10.33963/KP.a2021.0169. Epub 2021 Dec 3.
Mechanical circulatory support (MCS) methods are used in patients with both acute and chronic heart failure, who have exhausted other options for pharmacological or surgical treatments. The purpose of their use is to support, partially or completely, the failed ventricles and ensure adequate organ perfusion, which allows patients to restore full cardiovascular capacity, prolonging their life and effectively improving its quality. The three most popular devices include an intra-aortic balloon pump (IABP), percutaneous assist devices (including Impella, TandemHeart), and venoarterial extracorporeal membrane oxygenation (VA-ECMO). A multidisciplinary approach with the special participation of the Heart Team is required to determine the proper MCS strategy, the choice of the supporting method, and the time of its use. The studies published so far do not allow us to determine which MCS method is the safest and the most effective. Thus, the site experience and accessibility of the method seem to matter most today. MCS finds particular application in patients with acute coronary syndromes complicated by refractory cardiogenic shock, as well as in patients with acute heart failure of the high potential for reversibility. It can also serve as a backup for percutaneous coronary interventions of high risk (complex and high-risk indicated percutaneous coronary intervention [PCI], complex and high-risk indicated PCI [CHIP]). The use of appropriate supportive drugs, precise hemodynamic and echocardiographic monitoring, as well as optimal non-invasive or mechanical ventilation, are extremely important in the management of a patient with MCS. The most serious complications of MCS include bleeding, thromboembolic events, as well as infections, and hemolysis.
机械循环支持 (MCS) 方法用于急性和慢性心力衰竭患者,这些患者已经用尽了其他药物或手术治疗选择。其使用目的是部分或完全支持衰竭的心室并确保足够的器官灌注,使患者能够恢复充分的心血管功能,延长其生命并有效提高其生活质量。三种最流行的设备包括主动脉内球囊泵 (IABP)、经皮辅助设备(包括 Impella、TandemHeart)和静脉动脉体外膜肺氧合 (VA-ECMO)。需要多学科方法,特别需要心脏团队的参与,以确定适当的 MCS 策略、支持方法的选择及其使用时间。迄今为止发表的研究尚不能确定哪种 MCS 方法最安全和最有效。因此,目前看来,方法的现场经验和可及性似乎最重要。MCS 在急性冠状动脉综合征合并难治性心源性休克的患者中以及在高逆转可能性的急性心力衰竭患者中具有特殊应用。它还可以作为高风险(复杂和高风险指征经皮冠状动脉介入治疗 [PCI]、复杂和高风险指征 PCI [CHIP])经皮冠状动脉介入治疗的后备。在 MCS 患者的管理中,使用适当的支持药物、精确的血流动力学和超声心动图监测以及最佳的无创或机械通气非常重要。MCS 最严重的并发症包括出血、血栓栓塞事件以及感染和溶血。